The combination of olaparib (Lynparza) and abiraterone (Zytiga) in first-line treatment has produced a significant overall survival benefit in patients with metastatic castration-resistant prostate cancer (mCRPC). The study was presented at a meeting in San Francisco and described as "very impressive". The results showed a significant improvement in survival compared to standard therapy. The treatment was administered to patients with this type of advanced disease. The main finding is the prolongation of overall survival due to this combination. The study highlights the potential of combination therapy in the first line.